Larvol Delta - AffyImmune-Therapeutics-Announces-Positive-Safety-and-Early-Efcacy-Results-from-Phase-1-Study-of-AIC100-CAR-T-Cells-in-Anaplastic-and-Advanced-Thyroid-Cancers-at-2023-American-Society-of-Clinical-Oncology-ASCO-Annual-Meeting

AIC100 - AffyImmune Therap

https://www.prnewswire.com/news-releases/affyimmune-therapeutics-announces-positive-safety-and-early-efficacy-results-from-phase-1-study-of-aic100-car-t-cells-in-anaplastic-and-advanced-thyroid-cancers-at-2023-american-society-of-clinical-oncology-asco-annual-meeting-301834869.html

May 25, 2023

SHARE THIS

Print
Email
More sharing

Reddit

StumbleUpon

Delicious

Prev Next